Endometrial cancer (EC) is the sixth most commonly occurring cancer in women and its morbidity and mortality are continuously increasing. Considering experience with different types of cancers, C-reactive protein (CRP) appears to be a promising diagnostic and prognostic factor. Aiming to investigate its potential in view of EC authors of this paper reviewed databases for metanalysis, randomized controlled trials and review articles. Studies indicate CRP > 3.33 mg/l correlates with the EC incidence with HR = 2.29 (p < 0.05). Moreover, High-sensitivity CRP assay allows to detect CRP in very low concentrations and distinguish patients with endometriosis, soft tissue sarcomas and possibly EC. Perioperational CRP, as well as its changes are independent prognostic factors for EC. However, CRP-to-albumin ratio as well as Glasgow Prognostic Score (GPS) have greater prognostic value that CRP alone. Additionally, CRP is possibly a mediator of carcinogenesis and cancer progression through activation of inter alia FcgRs/MAPK/ERK, FcgRs/IL-6/AKT/STAT3 and FcgRs/NF-κB/NLRP3 pathways.

子宫内膜癌（EC）是女性中第六大最常见的癌症，其发病率和死亡率不断增加。考虑到不同类型癌症的经验，C 反应蛋白 (CRP) 似乎是一个很有前途的诊断和预后因素。鉴于本文的 EC 作者审查了荟萃分析、随机对照试验和评论文章的数据库，旨在调查其潜力。研究表明 CRP > 3.33 mg/l 与 EC 发病率相关，HR = 2.29 (p < 0.05)。此外，高灵敏度 CRP 测定可以检测极低浓度的 CRP，并区分患有子宫内膜异位症、软组织肉瘤和可能的 EC 的患者。围手术期 CRP 及其变化是 EC 的独立预后因素。然而，CRP/白蛋白比率以及格拉斯哥预后评分 (GPS) 比单独使用 CRP 具有更大的预后价值。此外，CRP 可能是通过激活尤其是 FcgRs/MAPK/ERK、FcgRs/IL-6/AKT/STAT3 和 FcgRs/NF-κB/NLRP3 途径的致癌作用和癌症进展的介质。